Acknowledgements This research was funded by National Basic Research Program of China (973 program 2014CB138600), National Natural Science Fund (31272676 and 31472290), and Program for New Century Excellent Talents in University
Structure Therapeutics is developing GSBR-1290, an oral small molecule GLP-1 agonist that could potentially address the manufacturing scalability challenges facing peptide-based injectablesthe company has noted its current manufacturing capacity could theoretically supply over 120 million patients [46]
In its simplest form, calculating a persons BAC level is based on how much alcohol went into what kind of body over a period of how much time
Contributing Researchers Recognized for published work that shaped the scientific context discussed above Predrag Sikiri, MD, PhD authored foundational research on BPC-157 in cytoprotection research [2]
Meet the experts: Jennifer Lucas, MD, is a dermatologist and dermatologic surgeon at the Cleveland Clinic